acute kidney damage acute kidney injury
Conditions
Interventions
30,000IU of bRESCAP or placebo
Sponsors
Nefrologie
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Age > 18 - Recipients of a donor awaiting cardiac death on the intensive care (definition of a donor cardiac death type III according to the *Maastricht classification*) - Written informed consent
Exclusion criteria
Exclusion criteria: - Strict vegetarians or vegans - History of allergy to bovine proteins
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| - Mean duration of hospitalization after kidney transplantation - Incidence of persistent dialysis DGF (> 14 days) - Incidence of DGF using functional and dialysis definition and a combination of the two - Duration of DGF using functional and dialysis definition and a combination of the two - Dall of serum creatinine in the first week after transplantation - Kidney perfusion contrast renography at day 6 - Creatinine clearance at 3 months and 1 year after transplantation - Proteinuria at 3 months and 1 year after transplantation - Estimated renal glomerular filtration rate (eGFR) calculated with MDRD and the CKD-epi formula at 3 months and 1 year after transplantation - Primary non-function (defined as dialysis dependency or creatinine clearance | — |
Primary
| Measure | Time frame |
|---|---|
| - Difference between treatment and placebo group in duration of delayed graft failure (DGF). DGF is defined as need for dialysis, excluding short sessions for hyperkalemia. DGF is defined as need for dialysis, excluding single sessions for hyperkalemia. | — |
Countries
Netherlands
Outcome results
None listed